观察|| 众生药业“流感牛”能否撑起50倍估值

粤股8
Nov 28, 2025

气温骤降与流感高发季重叠,A股市场对“流感概念”的追捧再度升温,众生药业(002317)成为资金追捧的焦点。11月中,公司股价一度冲高至27.97元,突破8月创下的阶段高点;这波凌厉的涨势直接将其动态市盈率推高至50倍以上,远超传统中药企业的平均估值水平。在资本市场的喧嚣之外,众生药业的业绩修复却步履蹒跚。尽管股价创出新高,公司核心流感新药昂拉地韦尚处于商业化初期,且公司前三季度营收增速也不亮眼。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10